Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

Maciocia, N; Melville, A; Cheesman, S; Sharpley, F; Ramasamy, K; Streetly, M; Jenner, M; ... Rabin, N; + view all Maciocia, N; Melville, A; Cheesman, S; Sharpley, F; Ramasamy, K; Streetly, M; Jenner, M; Benjamin, R; Schey, S; Maciocia, P; Popat, R; D'sa, S; Rismani, A; Cerner, A; Yong, K; Rabin, N; - view fewer (2017) Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. British Journal of Haematology , 176 (6) pp. 908-917. 10.1111/bjh.14547 . Green open access

https://ift.tt/2m649np